Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
Greenstein et al. • 2020 • AACR Annual Meeting 2020
© 2024 Corcept Therapeutics, Incorporated
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)
Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer
Munster et al. • 2019 •
Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.
Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.
Minireview: nuclear receptors and breast cancer.
Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.